Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

A Next-Generation Dual-Luciferase® Reporter Assay Using Firefly and NanoLuc® Luciferase

 

  • This webinar introduces:
    the Nano-Glo® Dual-Luciferase®  Reporter Assay System.

 

Summary

Luciferases are commonly used to monitor gene expression because of their broad dynamic range and extreme sensitivity. The dual-luciferase assay format is widely used to reduce experimental variability by comparing the response of the experimental reporter to that of a constitutively expressed control. In this way, variability arising from well-to-well or experiment-to-experiment differences in parameters such as transfection efficiency and cell number can be reduced or eliminated.

This webinar introduces the next-generation dual-luciferase assay, Nano-Glo® Dual-Luciferase® (NanoDLR™) Reporter Assay System, combining  firefly and NanoLuc® Luciferases.  The new assay offers the experimental freedom of the Dual-Glo® Reporter Assay System with regard to signal half-life and the brightness of the Dual-Luciferase® Reporter Assay System. 

The webinar also discusses the concept of the coincidence reporter assay, an assay developed at the NIH that is especially useful for monitoring reporter activity due to promoter activation in screening applications.  The coincidence reporter system is designed to identify false hits more rapidly so time and money are not wasted.


Speaker

chris-eggers-125x125

Christopher T. Eggers, PhD
Senior Research Scientist
Promega Corporation

Chris Eggers received his Ph.D. in biochemistry and molecular biology from the University of California at San Francisco, where he studied molecular recognition through structure/function analysis and protein engineering. He then completed a postdoctoral fellowship at the University of California at San Diego, identifying the role of a PKA-scaffolding protein in membrane trafficking. Chris has been at Promega since 2011, working primarily to develop new luminescence-based biosensors and reporter assays.

We love to talk science.

Sign up to receive monthly invitations to our webinars.

Sign Up